Dementia — diagnosis & management (Alzheimer, vascular, Lewy body, frontotemporal)
Neurocognitive disorder · Neurology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Acquired progressive decline in >=1 cognitive domain impairing function, with clear consciousness (distinguishes from delirium — covered). Commonest: Alzheimer (AD), vascular, dementia with Lewy bodies (DLB), frontotemporal (FTD). ED role: exclude/treat reversible causes & delirium, ensure safety/capacity, and initiate the diagnostic pathway. (BPSD covered separately.)
Red flags
- Rapidly progressive dementia (weeks-months) — prion disease (CJD), autoimmune/limbic encephalitis, CNS lymphoma, vasculitis — urgent work-up
- Fluctuating conscious level / acute change — delirium (find the cause)
- Gait apraxia + urinary incontinence + cognitive decline — normal pressure hydrocephalus (treatable — separate entry)
- Headache, focal signs, falls/anticoagulation — chronic subdural (treatable — separate entry)
- Young-onset (<65y), behavioural/language-led decline — FTD, needs specialist
- Neuroleptic sensitivity / severe reaction to antipsychotic — DLB
Assessment
Differential diagnosis
- Delirium (acute, fluctuating, inattention — covered) — ALWAYS exclude/co-exists
- Depression ('pseudodementia')
- Reversible causes: hypothyroidism, B12/folate deficiency, hypercalcaemia, neurosyphilis, HIV, normal pressure hydrocephalus (separate), chronic subdural (separate), medication effect, alcohol
- Mild cognitive impairment
- Subtype clues: AD (amnestic, insidious); vascular (stepwise, vascular risk/stroke); DLB (fluctuating cognition, visual hallucinations, parkinsonism, REM sleep behaviour disorder, neuroleptic sensitivity); FTD (behavioural/personality change or progressive aphasia, younger onset)
Investigations
- Cognitive testing: MMSE / MoCA / ACE-III; collateral history essential
- Screen reversible causes: FBC, U&E, Ca, glucose/HbA1c, LFT, TFT, B12 & folate; consider HIV, syphilis serology if indicated
- Exclude delirium: urinalysis/septic screen, medication review
- Neuroimaging (CT or MRI) — exclude subdural, tumour, NPH, vascular burden; MRI preferred for subtype (hippocampal/medial temporal atrophy in AD, vascular lesions)
- Specialist: DAT scan (DLB — reduced dopamine uptake), FDG-PET, CSF/plasma AD biomarkers (amyloid, p-tau) in selected cases
- Assess function, capacity, safety, driving, carer strain
Management
- Exclude and treat delirium and reversible causes first — do not diagnose dementia during acute illness
- Establish diagnosis and likely subtype with collateral history, cognitive testing and imaging; refer to memory clinic
- Safety & capacity: assess home safety, driving (advise against/notify licensing authority), medication management, falls, vulnerability, financial capacity; consider safeguarding
- Non-pharmacological first: cognitive stimulation, structured routine, carer education & support, advance care planning, Lasting Power of Attorney
- Start symptomatic drug therapy where indicated (specialist/memory clinic): cholinesterase inhibitors for mild-moderate AD and DLB; memantine for moderate-severe AD or add-on
- DLB: cholinesterase inhibitors (esp. rivastigmine) help cognition & hallucinations; AVOID antipsychotics (severe neuroleptic sensitivity) — if unavoidable use lowest-dose quetiapine cautiously
- Manage BPSD non-pharmacologically first (covered); treat vascular risk factors in vascular dementia
- Carer support, respite, community/old-age psychiatry referral; palliative approach as disease advances
Drugs & doses
Alzheimer / DLB (mild-moderate) cholinesterase inhibitor: donepezil 5 mg PO OD x4 weeks then 10 mg OD; OR rivastigmine (oral/patch 4.6-13.3 mg/24h patch); OR galantamine 8 mg OD titrated [verify local dose] — caution bradycardia/syncope, GI effects
Memantine 5 mg PO OD, titrate weekly by 5 mg to 20 mg/day — for moderate-severe AD, or add-on, or if cholinesterase inhibitor not tolerated
DLB: rivastigmine/donepezil help cognition and visual hallucinations; AVOID typical and most atypical antipsychotics (neuroleptic sensitivity reaction)
Anti-amyloid monoclonals (early AD, specialist, limited availability): lecanemab IV every 2 weeks; donanemab IV every 4 weeks — risk of ARIA; NOT approved on NHS (NICE rejected 2024-25); genotype/eligibility restricted [verify local availability]
Vascular dementia: no specific cognitive drug of proven benefit — optimise vascular risk (antihypertensives, statin, antiplatelet, diabetes, smoking)
Avoid/minimise anticholinergics, benzodiazepines and antipsychotics (worsen cognition, increase stroke/mortality in dementia)
Disposition
Outpatient memory clinic / old-age psychiatry referral for diagnosis and treatment initiation. Admit only for acute cause (delirium, treatable structural lesion), safeguarding crisis, or carer breakdown. Address capacity, safety and advance care planning.
Complications & pitfalls
- Delirium superimposed on dementia (recurrent admissions)
- Falls, malnutrition, aspiration pneumonia, pressure sores
- BPSD, carer burnout, safeguarding issues
- Loss of capacity, driving/financial risk
- Adverse drug effects (antipsychotic-related stroke/mortality, anticholinergic burden)
Exam pearls
- Always exclude delirium and reversible causes (B12, thyroid, Ca, drugs, subdural, NPH) before diagnosing dementia
- Cholinesterase inhibitors and memantine give modest symptomatic benefit; they do not halt progression
- DLB: visual hallucinations + fluctuating cognition + parkinsonism + REM sleep behaviour disorder — AVOID antipsychotics (life-threatening neuroleptic sensitivity)
- Anti-amyloid antibodies (lecanemab/donanemab) are new disease-modifying options for early AD but carry ARIA risk and are not NHS-funded (NICE rejected); availability limited [verify local]
- Rapidly progressive dementia warrants urgent investigation (CJD, autoimmune encephalitis) — do not attribute to ordinary dementia
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.